Phibro Animal Health CORP: management transactions · United States · SEC (Form 4)

About Phibro Animal Health CORP

Phibro Animal Health Corp. (Nasdaq: PAHC) is a United States-listed company on the NASDAQ market, headquartered in Teaneck, New Jersey, United States. For French-speaking investors, Phibro fits the profile of a specialist animal-health and mineral-nutrition business, with exposure to end markets that are often relatively defensive, but still influenced by livestock cycles, feed costs, disease pressure and regional agricultural conditions. The company develops, manufactures and markets a broad portfolio of products for food-producing and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. Its product set spans disease prevention and treatment solutions, medicated feed additives, water-soluble products, nutritional specialties, vaccines and certain ingredients also used in personal care, industrial chemical and chemical-catalyst applications. Phibro reports its operations across three segments: Animal Health, Mineral Nutrition and Performance Products. Historically, the company traces its roots back many decades and has evolved from an industrial chemicals heritage into a focused animal-health platform. It has operated under the Phibro Animal Health Corporation name since 2003 and became a NASDAQ-listed public company in 2014. That history is important for investors because it shows a business model built through a combination of organic development, proprietary products and targeted acquisitions. The most significant recent strategic step was the completed acquisition on October 31, 2024, of Zoetis’s medicated feed additive portfolio and certain water-soluble products and related assets. That transaction expanded Phibro’s scale, broadened its product offering and increased its manufacturing footprint. Phibro has a global commercial and manufacturing presence, with sales across a wide international footprint and production assets in the United States, Europe, Latin America and Asia. This geographic diversification gives the company access to major livestock markets and helps balance demand across regions. Competitive positioning is based on its combination of animal health, nutrition and performance products, along with its broad franchise in livestock-focused solutions and a growing companion-animal pipeline. Recent developments have been material. In fiscal 2025 and into 2026, Phibro reported strong revenue and earnings growth, supported in part by the Zoetis acquisition integration and improved operating momentum. The company also announced new initiatives in 2025 in canine oral health, underscoring efforts to expand beyond traditional livestock categories. In late 2025, Phibro announced a leadership transition, indicating continued strategic evolution and execution focus. Overall, Phibro presents as a mid-sized but diversified animal-health platform with international reach, a long operating history and a recent acquisition-led growth phase.